https://www.selleckchem.com/pr....oducts/Elesclomol.ht
Nonalcoholic steatohepatitis (NASH) is a common cause of chronic liver disease. There is a major need to understand the efficacy of different pharmacological agents for the treatment of NASH. To assess the relative rank-order of different pharmacological interventions in fibrosis improvement and NASH resolution. A comprehensive search of several databases was conducted by an experienced librarian. We included randomised controlled-trials (RCTs) comparing pharmacological interventions in patients with biopsy-proven NASH. The primary o
Like
Comment
Share
